Developer docs
API playgroundTry for free, no card

Search company profiles

Viriom

Full company profile

uuid0002lu3

Namestring
Viriom
Legal namestring
Viriom, Inc.
Websiteurl
viriom.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Viriom, Inc. is a privately-held, clinical- and commercial-stage biopharmaceutical company founded in 2009 and headquartered in San Diego, California, with operational offices in Rockville (Maryland), Moscow, Beijing, and a Hong Kong affiliate in build-out. The company focuses on developing and commercializing antiviral therapies for HIV-1, hepatitis B and C, COVID-19, and influenza, plus an oncology program (Quisinostat HDAC1 inhibitor) for platinum-resistant ovarian cancer and other solid tumors. Its pipeline and commercial portfolio rest on an exclusive worldwide license from F. Hoffmann-La Roche covering the elsulfavirine/VM1500A compound family, supplemented by nanoparticle long-acting injectable (LAI) formulation technology, an in-licensed Quisinostat estate from Janssen Pharmaceuticals, and over 20 patents and patent applications across nine antiretroviral candidates and PrEP/PEP programs.

The commercial core consists of three approved products: Elpida® (elsulfavirine 20 mg once-daily oral NNRTI), marketed in Russia and EAEU since June 2017 and listed on Russia's Vital and Essential Drugs List since September 2018; AGAPE® FDC (elsulfavirine + tenofovir disoproxil fumarate + emtricitabine), approved in Russia and EAEU in 2022; and Depulfavirine (DPV), a nanosphere long-acting injectable. Avifavir, the world's first favipiravir-based COVID-19 drug, received full market authorization in November 2020 and was distributed to over 1 million patients across 17 countries in 2020-2021. Developmental assets include VM1500A-LAI (Phase 2a, monthly/quarterly injectable), once-weekly oral elsulfavirine for PrEP/PEP (FDA IND accepted), VM3500 long-acting injectable INSTI (preclinical), AV5124/AV5125 influenza RNA-processing inhibitor (Phase 1 complete in November 2023), and Quisinostat (Phase II).

Viriom monetizes primarily through partner-driven commercialization: direct sales to government health authorities (notably Russia's federal and regional HIV programs), out-licensing and technology transfer agreements with regional pharma partners (e.g., P.T. Lloyd Pharma in Indonesia, Pratapa Nirmala-Fahrenheit for Avifavir), and OEM/manufacturing relationships (ChemRar Group for Favipiravir production, ChemDiv). Capital formation has combined equity rounds — including a $12.5M Pharmstandard investment in December 2017 and a $4.7M raise in October 2023 — with non-dilutive grant funding from The Skolkovo Foundation, NIH/NIAID, and Shaoxing (China) talent awards. Pricing is not publicly disclosed, but the company positions its products as affordable for both developed and developing markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral drug development, HIV therapeutics, antiretroviral therapy, infectious disease treatments, antiviral pharmaceuticals
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiviral Pharmaceuticals
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Branded Antiviral Drug Sales (Elpida® / Agape® / Avifavir)
TypeHardware Sales
Description

Direct commercialization and partner-distributed sales of approved drugs: Elpida® (elsulfavirine) in Russia and EAEU since 2017, Agape® FDC in Russia/EAEU from 2022, and Avifavir delivered to over 1 million patients across 17 countries in 2020-2021.

viriom.com
2Out-licensing and Territory Royalties
TypeLicensing Royalties
Description

Licensing agreements with regional partners (e.g., P.T. Lloyd Pharma in Indonesia for Elpida; Pratapa Nirmala-Fahrenheit for Avifavir registration and sales in Indonesia) generating upfront, milestone, and royalty income plus technology transfer and local packaging/manufacturing.

viriom.com
3Non-Dilutive Grant Funding
TypeManaged Services
Description

Grant-based funding from foundations and government programs, including a three-year 150 million rubles grant from The Skolkovo Foundation to Viriom Ltd for development of new Elpida® formulations.

chemdiv.com
4Equity Financing
TypeOne Time License
Description

Equity capital raised alongside grants, contributing to a combined $4.7 million funding round reported in 2023.

chemdiv.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Elpida®
Description

Brand name for Elsulfavirine, an antiretroviral therapy.

viriom.com
+2 more records
Core offering1 text field

Viriom develops and commercializes small-molecule antiviral drugs for HIV-1 (Elpida®/elsulfavirine oral NNRTI, AGAPE® triple fixed-dose combination, Depulfavirine monthly nanosphere injectable), COVID-19 (Avifavir/Favipiravir oral antiviral), and a clinical-stage pipeline in influenza, hepatitis B/C, and oncology. Its lead HIV assets were licensed from F. Hoffmann-La Roche in 2009 and are commercialized in Russia, EAEU, China, and Indonesia via direct sales to government health programs and out-licensing to regional pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Elpida® safety/tolerability 2-4x better than efavirenz 600mg; CNS adverse events and rash/allergy significantly lower
+4 more records
Product overview1 text field

Viriom operates as a single biotech platform that advances a unified pipeline of antivirals and oncology therapies for global markets, rather than a multi-product SaaS portfolio. Its commercial core consists of Elpida® (elsulfavirine) and its marketed extensions — the AGAPE® fixed-dose combination and Depulfavirine (DPV) injectable — for HIV-1, alongside Favipiravir/Avifavir for SARS-CoV-2. These commercial assets sit beside a developmental layer of investigational programs: elsulfavirine+NRTI/INSTI fixed-dose combinations and the long-acting injectable VM3500 for HIV-1, the AV5124/AV5125 program for seasonal and pandemic influenza, and Quisinostat for oncology. The entire portfolio is built on a shared small-molecule antiviral and drug development platform, with key HIV assets originally licensed from F. Hoffmann-La Roche.

Product and service4 records
1Elpida® (elsulfavirine)
CategoryHIV-1 antiretroviral (NNRTI) — marketed drug
Description

Once-daily 20 mg oral capsule of elsulfavirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) and prodrug of VM1500A (RO4970335), indicated for the treatment of HIV-1 infection in combination with other antiretrovirals. Licensed from F. Hoffmann-La Roche and marketed in Russia and EurAsEC countries.

2AGAPE® Fixed-Dose Combination (FDC)
CategoryHIV-1 antiretroviral (triple FDC) — marketed drug
Description

Once-daily single-tablet triple fixed-dose combination of elsulfavirine 20 mg + tenofovir disoproxil fumarate 200 mg + emtricitabine 300 mg for treatment of HIV-1 infection; approved for marketing in Russia and EurAsEC countries in 2022.

3Depulfavirine (DPV) Long-Acting Injectable
CategoryHIV-1 long-acting injectable (NNRTI nanosphere) — marketed drug
Description

Nanosphere injectable formulation of VM1500A designed for once-monthly or less-frequent use in combination therapy for HIV-1 infection, built on the VM1500A-LAI platform with 7.5-day plasma half-life enabling sustained therapeutic drug levels.

4Avifavir (Favipiravir)
CategoryCOVID-19 antiviral (RNA polymerase inhibitor) — marketed drug
Description

Oral antiviral (RNA polymerase inhibitor) marketed under the brand name Avifavir for the treatment of SARS-CoV-2 infection and COVID-19; the world's first favipiravir-based drug approved for COVID-19, with full market authorization in November 2020 and subsequent registrations across 17 countries, delivering over 1 million treatment courses in 2020-2021.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-07-02
Description

Signed licensing agreement in July 2019 as part of Viriom's global strategy to combat HIV drug resistance in developing markets. The agreement enables technology transfer and local primary/secondary packaging and drug manufacturing in Indonesia for Elpida® and other Viriom HIV/HBV portfolio products.

Strategic tierCoreTypeOthersAnnounced on2017-12-06
Description

Managing Partner of HealthCare Ventures (over 17 years) appointed to Viriom's Board of Directors in December 2017. Brings biotech strategic operations, finance, M&A, and corporate development experience.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2009-01-01
Description

In 2009 Viriom licensed from F. Hoffmann-La Roche a family of patents and drug candidates that gave rise to Elpida® (elsulfavirine) and VM1500A. The license is exclusive worldwide, covering the oral NNRTI pro-drug and long-acting injectable VM1500A-LAI drug candidate for HIV-1 treatment and prevention. This license underpins Viriom's lead asset and the foundation of its HIV pipeline.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Local Indonesian partner for the registration and sales of Avifavir (Favipiravir) in Indonesia, supporting Viriom's first COVID-19 drug registration in Asia.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Viriom-affiliated ChemRar Group manufactures Favipiravir for use in combination formulations (with Elsulfavirine) being studied for treatment of severe COVID-19 infection. ChemRar supports Viriom's COVID-19 antiviral development efforts.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Originated the Quisinostat HDAC1 inhibitor asset that Viriom is developing for platinum-resistant ovarian cancer and other solid tumors. Viriom supports new indications in combination with standard of care or experimental agents.

7National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS, NIH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIAID Division of AIDS provided preclinical services to support Viriom's Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) once-weekly oral formulation, a critical step for FDA approval of the once-weekly regimen in the US.

viriom.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

SRI International executed the Segment I and Segment II reproductive toxicity preclinical studies for Viriom's Elpida® (elsulfavirine) once-weekly oral formulation, supporting FDA drug approval requirements.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Covance executed preclinical reproductive toxicity studies supporting the FDA approval pathway for Viriom's Elpida® (elsulfavirine) once-weekly oral formulation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ChemDiv is listed as a Viriom partner on the 'Our Partners' page, supporting Viriom's global drug development platform. ChemRar Group (an affiliate) manufactures Favipiravir for Viriom's COVID-19 combination therapy program.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

Listed as a Viriom partner and the originator of the Elpida® (elsulfavirine) and VM1500A patents licensed to Viriom in 2009.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Viriom partner on the 'Our Partners' page, supporting the company's global drug development platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Viriom partner supporting the company's drug development and registration efforts in Thailand and Southeast Asia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Viriom partner supporting the company's drug development platform.

15Mahidol University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Viriom partner supporting the company's drug development platform.

viriom.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Viriom partner supporting drug formulation and development efforts.

17Robert Redfield, MD (Advisory Board)
Strategic tierCoreTypeOthers
Description

Former Director of the U.S. Centers for Disease Control and Prevention (CDC) serves on Viriom's Advisory Board, lending clinical and public-health expertise to Viriom's infectious disease programs.

viriom.com
18Dr. Seth Berkley (Advisory Board)
Strategic tierCoreTypeOthers
Description

CEO of GAVI Alliance and affiliated with the International AIDS Vaccine Initiative, advising Viriom on Global Access strategy.

viriom.com
19Dr. Douglas Richman (Advisory Board)
Strategic tierCoreTypeOthers
Description

Director of the Center for AIDS Research at UC San Diego, advising Viriom on Clinical Virology.

viriom.com
20Dr. Yiming Shao (Advisory Board)
Strategic tierCoreTypeOthers
Description

Affiliated with the Chinese Center for Disease Control and Prevention and National Center for AIDS/STD Control and Prevention, advising Viriom on China market access and HIV strategy.

viriom.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Merck markets doravirine (Pifeltro) and Delstrigo in the NNRTI class where Viriom's elsulfavirine competes, and also developed molnupiravir (Lagevrio) for COVID-19, directly competing with Viriom's Avifavir. Merck is a broad incumbent with overlapping mechanisms in both therapeutic areas Viriom addresses.

TypeEmerging player
Description

Theratechnologies commercializes Trogarzo (ibalizumab) in North America and Europe, focused on heavily treatment-experienced HIV patients. It is comparable to Viriom as a smaller, commercial-stage HIV-focused company pursuing differentiated, resistance-overcoming therapies.

TypeEmerging player
Description

Arcturus developed a self-amplifying mRNA COVID-19 vaccine and has LAI technology programs, including in infectious disease. While the modality differs, Arcturus is a useful comparable as a small-cap clinical-stage biotech pursuing long-acting delivery platforms with multiple infectious-disease indications.

TypeEmerging player
Description

TaiMed developed ibalizumab (Trogarzo), an approved HIV entry inhibitor with an intravenous administration profile, and is exploring LAI formulations. It is a smaller specialty HIV company comparable in scale and stage to Viriom, focused on differentiated mechanisms and niche/resistance-driven indications.

TypeRegional player
Description

Brii Biosciences is a China-headquartered biotech with programs in HIV (long-acting combinations) and infectious diseases. Like Viriom, it pursues a developing-market access strategy with strong China positioning and overlaps with Viriom's Asia HIV and COVID-19 efforts.

TypeDirect peer
Description

FUJIFILM Toyama Chemical is the originator of favipiravir (Avigan), the active pharmaceutical ingredient in Viriom's Avifavir. It is a direct peer in the favipiravir-based antiviral space and a key supply/competitive consideration for Viriom's COVID-19 and influenza programs.

TypeDirect peer
Description

ViiV Healthcare is the global HIV specialist majority-owned by GSK and develops both NNRTIs, NRTIs, INSTIs, and the only approved long-acting injectable regimen (cabotegravir/rilpivirine, marketed as Cabenuva and Apretude). Viriom's Elpida® (NNRTI), Depulfavirine (LAI NNRTI), and VM3500 (LAI INSTI) directly target the same patient population and delivery paradigm.

TypeBroad incumbent
Description

Gilead is the dominant HIV antiviral franchise globally (Biktarvy, Descovy, Sunlenca LAI) and a major player in antiviral drug development. Viriom competes on the same NNRTI/INSTI/NRTI axes but with a focus on affordability and developing-market access rather than US/EU dominance.

9Frontier Biotechnologies
TypeDirect peer
Description

China-based Frontier Biotech developed albuvirtide, the first long-acting injectable fusion inhibitor for HIV approved in China. It is the closest peer in terms of LAI HIV technology, developing-market focus, and emerging-market regulatory strategy, making it directly comparable to Viriom's Depulfavirine/VM1500A-LAI program.

TypeBroad incumbent
Description

Shionogi is a Japanese pharma with both an HIV franchise (including a long-acting injectable in development via partnership) and ensitrelvir (Xocova), an oral COVID-19 antiviral approved in Japan. Comparable to Viriom as a mid-sized antiviral-focused innovator operating in both HIV and acute respiratory viral disease markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viriom

Antiviral Pharmaceuticalsviriom.com

What Viriom does

Viriom, Inc. is a privately-held, clinical- and commercial-stage biopharmaceutical company founded in 2009 and headquartered in San Diego, California, with operational offices in Rockville (Maryland), Moscow, Beijing, and a Hong Kong affiliate in build-out. The company focuses on developing and commercializing antiviral therapies for HIV-1, hepatitis B and C, COVID-19, and influenza, plus an oncology program (Quisinostat HDAC1 inhibitor) for platinum-resistant ovarian cancer and other solid tumors. Its pipeline and commercial portfolio rest on an exclusive worldwide license from F. Hoffmann-La Roche covering the elsulfavirine/VM1500A compound family, supplemented by nanoparticle long-acting injectable (LAI) formulation technology, an in-licensed Quisinostat estate from Janssen Pharmaceuticals, and over 20 patents and patent applications across nine antiretroviral candidates and PrEP/PEP programs.

The commercial core consists of three approved products: Elpida® (elsulfavirine 20 mg once-daily oral NNRTI), marketed in Russia and EAEU since June 2017 and listed on Russia's Vital and Essential Drugs List since September 2018; AGAPE® FDC (elsulfavirine + tenofovir disoproxil fumarate + emtricitabine), approved in Russia and EAEU in 2022; and Depulfavirine (DPV), a nanosphere long-acting injectable. Avifavir, the world's first favipiravir-based COVID-19 drug, received full market authorization in November 2020 and was distributed to over 1 million patients across 17 countries in 2020-2021. Developmental assets include VM1500A-LAI (Phase 2a, monthly/quarterly injectable), once-weekly oral elsulfavirine for PrEP/PEP (FDA IND accepted), VM3500 long-acting injectable INSTI (preclinical), AV5124/AV5125 influenza RNA-processing inhibitor (Phase 1 complete in November 2023), and Quisinostat (Phase II).

Viriom monetizes primarily through partner-driven commercialization: direct sales to government health authorities (notably Russia's federal and regional HIV programs), out-licensing and technology transfer agreements with regional pharma partners (e.g., P.T. Lloyd Pharma in Indonesia, Pratapa Nirmala-Fahrenheit for Avifavir), and OEM/manufacturing relationships (ChemRar Group for Favipiravir production, ChemDiv). Capital formation has combined equity rounds — including a $12.5M Pharmstandard investment in December 2017 and a $4.7M raise in October 2023 — with non-dilutive grant funding from The Skolkovo Foundation, NIH/NIAID, and Shaoxing (China) talent awards. Pricing is not publicly disclosed, but the company positions its products as affordable for both developed and developing markets.

Viriom firmographics

Firmographics
Name
Viriom
Legal name
Viriom, Inc.
Website
https://viriom.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Viriom industry classification

Industry
Product category
Antiviral Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antiviral drug development
  • HIV therapeutics
  • Antiretroviral therapy
  • Infectious disease treatments
  • Antiviral pharmaceuticals

Where Viriom is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Viriom business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Branded Antiviral Drug Sales (Elpida® / Agape® / Avifavir): Direct commercialization and partner-distributed sales of approved drugs: Elpida® (elsulfavirine) in Russia and EAEU since 2017, Agape® FDC in Russia/EAEU from 2022, and Avifavir delivered to over 1 million patients across 17 countries in 2020-2021.
  2. Out-licensing and Territory Royalties: Licensing agreements with regional partners (e.g., P.T. Lloyd Pharma in Indonesia for Elpida; Pratapa Nirmala-Fahrenheit for Avifavir registration and sales in Indonesia) generating upfront, milestone, and royalty income plus technology transfer and local packaging/manufacturing.
  3. Non-Dilutive Grant Funding: Grant-based funding from foundations and government programs, including a three-year 150 million rubles grant from The Skolkovo Foundation to Viriom Ltd for development of new Elpida® formulations.
  4. Equity Financing: Equity capital raised alongside grants, contributing to a combined $4.7 million funding round reported in 2023.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

Viriom product offering

Product offering

Core offering

Viriom develops and commercializes small-molecule antiviral drugs for HIV-1 (Elpida®/elsulfavirine oral NNRTI, AGAPE® triple fixed-dose combination, Depulfavirine monthly nanosphere injectable), COVID-19 (Avifavir/Favipiravir oral antiviral), and a clinical-stage pipeline in influenza, hepatitis B/C, and oncology. Its lead HIV assets were licensed from F. Hoffmann-La Roche in 2009 and are commercialized in Russia, EAEU, China, and Indonesia via direct sales to government health programs and out-licensing to regional pharmaceutical partners.

Product overview

Viriom operates as a single biotech platform that advances a unified pipeline of antivirals and oncology therapies for global markets, rather than a multi-product SaaS portfolio. Its commercial core consists of Elpida® (elsulfavirine) and its marketed extensions — the AGAPE® fixed-dose combination and Depulfavirine (DPV) injectable — for HIV-1, alongside Favipiravir/Avifavir for SARS-CoV-2. These commercial assets sit beside a developmental layer of investigational programs: elsulfavirine+NRTI/INSTI fixed-dose combinations and the long-acting injectable VM3500 for HIV-1, the AV5124/AV5125 program for seasonal and pandemic influenza, and Quisinostat for oncology. The entire portfolio is built on a shared small-molecule antiviral and drug development platform, with key HIV assets originally licensed from F. Hoffmann-La Roche.

Differentiator

Problem solved

Functional benefit

Brands

  • Elpida®: Brand name for Elsulfavirine, an antiretroviral therapy.
  • Avifavir
  • Agape®

Products and services

  • Elpida® (elsulfavirine) Once-daily 20 mg oral capsule of elsulfavirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) and prodrug of VM1500A (RO4970335), indicated for the treatment of HIV-1 infection in combination with other antiretrovirals. Licensed from F. Hoffmann-La Roche and marketed in Russia and EurAsEC countries.
  • AGAPE® Fixed-Dose Combination (FDC) Once-daily single-tablet triple fixed-dose combination of elsulfavirine 20 mg + tenofovir disoproxil fumarate 200 mg + emtricitabine 300 mg for treatment of HIV-1 infection; approved for marketing in Russia and EurAsEC countries in 2022.
  • Depulfavirine (DPV) Long-Acting Injectable Nanosphere injectable formulation of VM1500A designed for once-monthly or less-frequent use in combination therapy for HIV-1 infection, built on the VM1500A-LAI platform with 7.5-day plasma half-life enabling sustained therapeutic drug levels.
  • Avifavir (Favipiravir) Oral antiviral (RNA polymerase inhibitor) marketed under the brand name Avifavir for the treatment of SARS-CoV-2 infection and COVID-19; the world's first favipiravir-based drug approved for COVID-19, with full market authorization in November 2020 and subsequent registrations across 17 countries, delivering over 1 million treatment courses in 2020-2021.

Quantifiable outcome

  • Elpida® safety/tolerability 2-4x better than efavirenz 600mg; CNS adverse events and rash/allergy significantly lower
  • +4 more outcomes

Companies that use Viriom

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles3 records

Viriom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Viriom partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core, flagship and minor.

  • P.T. Lloyd PharmacoreChannel Partner/ Reseller/ Distributor · 2 July 2019Signed licensing agreement in July 2019 as part of Viriom's global strategy to combat HIV drug resistance in developing markets. The agreement enables technology transfer and local primary/secondary packaging and drug manufacturing in Indonesia for Elpida® and other Viriom HIV/HBV portfolio products.
  • Augustine LawlorcoreOthers · 6 December 2017Managing Partner of HealthCare Ventures (over 17 years) appointed to Viriom's Board of Directors in December 2017. Brings biotech strategic operations, finance, M&A, and corporate development experience.
  • F. Hoffmann-La RocheflagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2009In 2009 Viriom licensed from F. Hoffmann-La Roche a family of patents and drug candidates that gave rise to Elpida® (elsulfavirine) and VM1500A. The license is exclusive worldwide, covering the oral NNRTI pro-drug and long-acting injectable VM1500A-LAI drug candidate for HIV-1 treatment and prevention. This license underpins Viriom's lead asset and the foundation of its HIV pipeline.
  • Pratapa Nirmala-FahrenheitcoreChannel Partner/ Reseller/ DistributorLocal Indonesian partner for the registration and sales of Avifavir (Favipiravir) in Indonesia, supporting Viriom's first COVID-19 drug registration in Asia.
  • ChemRar GroupcoreStrategic or Co-development PartnerViriom-affiliated ChemRar Group manufactures Favipiravir for use in combination formulations (with Elsulfavirine) being studied for treatment of severe COVID-19 infection. ChemRar supports Viriom's COVID-19 antiviral development efforts.
  • Janssen PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerOriginated the Quisinostat HDAC1 inhibitor asset that Viriom is developing for platinum-resistant ovarian cancer and other solid tumors. Viriom supports new indications in combination with standard of care or experimental agents.
  • National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS, NIHcoreStrategic or Co-development PartnerNIAID Division of AIDS provided preclinical services to support Viriom's Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) once-weekly oral formulation, a critical step for FDA approval of the once-weekly regimen in the US.
  • SRI InternationalminorImplementation/ SI/ Consulting PartnerSRI International executed the Segment I and Segment II reproductive toxicity preclinical studies for Viriom's Elpida® (elsulfavirine) once-weekly oral formulation, supporting FDA drug approval requirements.
  • CovanceminorImplementation/ SI/ Consulting PartnerCovance executed preclinical reproductive toxicity studies supporting the FDA approval pathway for Viriom's Elpida® (elsulfavirine) once-weekly oral formulation.
  • ChemDivcoreStrategic or Co-development PartnerChemDiv is listed as a Viriom partner on the 'Our Partners' page, supporting Viriom's global drug development platform. ChemRar Group (an affiliate) manufactures Favipiravir for Viriom's COVID-19 combination therapy program.
  • RocheflagshipOEM/ Whitelabel/ Licensing PartnerListed as a Viriom partner and the originator of the Elpida® (elsulfavirine) and VM1500A patents licensed to Viriom in 2009.
  • Scripps ResearchminorStrategic or Co-development PartnerListed as a Viriom partner on the 'Our Partners' page, supporting the company's global drug development platform.
  • TCELS (Thailand Center of Excellence for Life Sciences)minorStrategic or Co-development PartnerListed as a Viriom partner supporting the company's drug development and registration efforts in Thailand and Southeast Asia.
  • Heidelberg UniversityminorStrategic or Co-development PartnerListed as a Viriom partner supporting the company's drug development platform.
  • Mahidol UniversityminorStrategic or Co-development PartnerListed as a Viriom partner supporting the company's drug development platform.
  • IriSysminorStrategic or Co-development PartnerListed as a Viriom partner supporting drug formulation and development efforts.
  • Robert Redfield, MD (Advisory Board)coreOthersFormer Director of the U.S. Centers for Disease Control and Prevention (CDC) serves on Viriom's Advisory Board, lending clinical and public-health expertise to Viriom's infectious disease programs.
  • Dr. Seth Berkley (Advisory Board)coreOthersCEO of GAVI Alliance and affiliated with the International AIDS Vaccine Initiative, advising Viriom on Global Access strategy.
  • Dr. Douglas Richman (Advisory Board)coreOthersDirector of the Center for AIDS Research at UC San Diego, advising Viriom on Clinical Virology.
  • Dr. Yiming Shao (Advisory Board)coreOthersAffiliated with the Chinese Center for Disease Control and Prevention and National Center for AIDS/STD Control and Prevention, advising Viriom on China market access and HIV strategy.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Viriom competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Merck markets doravirine (Pifeltro) and Delstrigo in the NNRTI class where Viriom's elsulfavirine competes, and also developed molnupiravir (Lagevrio) for COVID-19, directly competing with Viriom's Avifavir. Merck is a broad incumbent with overlapping mechanisms in both therapeutic areas Viriom addresses.
  • Gilead Sciences: Gilead is the dominant HIV antiviral franchise globally (Biktarvy, Descovy, Sunlenca LAI) and a major player in antiviral drug development. Viriom competes on the same NNRTI/INSTI/NRTI axes but with a focus on affordability and developing-market access rather than US/EU dominance.
  • Shionogi: Shionogi is a Japanese pharma with both an HIV franchise (including a long-acting injectable in development via partnership) and ensitrelvir (Xocova), an oral COVID-19 antiviral approved in Japan. Comparable to Viriom as a mid-sized antiviral-focused innovator operating in both HIV and acute respiratory viral disease markets.

Emerging players

  • Theratechnologies: Theratechnologies commercializes Trogarzo (ibalizumab) in North America and Europe, focused on heavily treatment-experienced HIV patients. It is comparable to Viriom as a smaller, commercial-stage HIV-focused company pursuing differentiated, resistance-overcoming therapies.
  • Arcturus Therapeutics: Arcturus developed a self-amplifying mRNA COVID-19 vaccine and has LAI technology programs, including in infectious disease. While the modality differs, Arcturus is a useful comparable as a small-cap clinical-stage biotech pursuing long-acting delivery platforms with multiple infectious-disease indications.
  • TaiMed Biologics: TaiMed developed ibalizumab (Trogarzo), an approved HIV entry inhibitor with an intravenous administration profile, and is exploring LAI formulations. It is a smaller specialty HIV company comparable in scale and stage to Viriom, focused on differentiated mechanisms and niche/resistance-driven indications.

Regional players

  • Brii Biosciences: Brii Biosciences is a China-headquartered biotech with programs in HIV (long-acting combinations) and infectious diseases. Like Viriom, it pursues a developing-market access strategy with strong China positioning and overlaps with Viriom's Asia HIV and COVID-19 efforts.

Direct peers

  • FUJIFILM Toyama Chemical: FUJIFILM Toyama Chemical is the originator of favipiravir (Avigan), the active pharmaceutical ingredient in Viriom's Avifavir. It is a direct peer in the favipiravir-based antiviral space and a key supply/competitive consideration for Viriom's COVID-19 and influenza programs.
  • ViiV Healthcare: ViiV Healthcare is the global HIV specialist majority-owned by GSK and develops both NNRTIs, NRTIs, INSTIs, and the only approved long-acting injectable regimen (cabotegravir/rilpivirine, marketed as Cabenuva and Apretude). Viriom's Elpida® (NNRTI), Depulfavirine (LAI NNRTI), and VM3500 (LAI INSTI) directly target the same patient population and delivery paradigm.
  • Frontier Biotechnologies: China-based Frontier Biotech developed albuvirtide, the first long-acting injectable fusion inhibitor for HIV approved in China. It is the closest peer in terms of LAI HIV technology, developing-market focus, and emerging-market regulatory strategy, making it directly comparable to Viriom's Depulfavirine/VM1500A-LAI program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Viriom social profiles

Digital presence

Viriom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viriom leadership team

Management profile

Number of profiles

Profiles13 records

Viriom subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Viriom funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viriom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viriom

What does Viriom do?

Viriom develops and commercializes small-molecule antiviral drugs for HIV-1 (Elpida®/elsulfavirine oral NNRTI, AGAPE® triple fixed-dose combination, Depulfavirine monthly nanosphere injectable), COVID-19 (Avifavir/Favipiravir oral antiviral), and a clinical-stage pipeline in influenza, hepatitis B/C, and oncology. Its lead HIV assets were licensed from F. Hoffmann-La Roche in 2009 and are commercialized in Russia, EAEU, China, and Indonesia via direct sales to government health programs and out-licensing to regional pharmaceutical partners.

Is Viriom a public or private company?

Viriom is a private company. It is classified as venture growth investor backed and is currently operating.

When was Viriom founded?

Viriom was founded in 2009. It employs 1 to 10 people.

Where is Viriom based?

Viriom is headquartered in San Diego, United States, in the North America region.

How does Viriom make money?

Four revenue lines are on record. Branded Antiviral Drug Sales (Elpida® / Agape® / Avifavir) is the primary driver. The others are out-licensing and Territory Royalties, non-Dilutive Grant Funding and equity Financing.

Who are Viriom's main competitors?

Broad incumbents on record are Merck & Co., Gilead Sciences and Shionogi. Emerging players are Theratechnologies, Arcturus Therapeutics and TaiMed Biologics. Brii Biosciences is listed as a regional player. Direct peers are FUJIFILM Toyama Chemical, ViiV Healthcare and Frontier Biotechnologies.

Does Viriom have an API?

No public API is recorded for Viriom.

What industry is Viriom in?

Viriom's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Daily TrustMusa Bello, AMA Foundation chair, makes case for homegrown health securityMusa Bello, chair of the AMA Foundation, presented at the WHO headquarters in Geneva advocating for local pharmaceutical manufacturing in Africa, using Nigeria’s AMA Medical Manufacturing Ltd (AMA-MED) as a model for self-reliance. The initiative highlights strategic partnerships with Barbados Pharmaceuticals Inc and technology support from Viriom Inc and MicroPharm UK to produce essential medicines like IV fluids and HIV treatments locally.PR NewswireHDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsightDelveInsight has released a comprehensive HDAC inhibitors market report covering the 7MM (United States, EU-4, United Kingdom, and Japan) for the period 2020–2034, projecting significant market growth driven by rising cancer prevalence and expanding pipeline activity. Key pipeline drugs including Abexinostat (Xynomic Pharmaceuticals, Phase III for renal cell carcinoma), Quisinostat (Viriom, Phase II for uveal melanoma), and Entinostat (EOC Pharma/Syndax, for Hodgkin lymphoma) are advancing through clinical trials, alongside approved therapies such as DUVYZAT (Italfarmaco) and HIYASTA (HUYA Bioscience International). The report identifies market challenges including drug toxicity, competition from newer targeted therapies, and late-stage trial failures, while noting that combination approaches and precision oncology trends may drive future growth.PR NewswireViriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021Viriom Inc. and Chromis published results of a multi-center open-label post-marketing clinical study of Avifavir (favipiravir) in 940 hospitalized COVID-19 patients at CROI2021, showing statistically significant improvements over Standard of Supportive Care including 33% faster viral clearance (8 vs 12 days), 20% shorter time to clinical improvement (12 vs 15 days), and 31% lower mortality (5.7% vs 8.3%). Avifavir received emergency use authorization from Russia's Ministry of Health in May 2020 and full market authorization in November 2020, having been delivered to over 1,000,000 patients in 17 countries, with rolling review submissions planned with the EMA and US FDA.PR NewswireElpida (elsulfavirine) becomes the preferred first line therapy for treatment of HIV infection in RussiaViriom Inc announced that its antiviral drug Elpida (elsulfavirine) has been included in the preferred first-line antiretroviral therapy regimens by the Russian Ministry of Health according to updated HIV treatment guidelines for adults and children. Clinical trials demonstrated strong efficacy, with over 90% of treatment-naive patients achieving undetectable viral load after 48 weeks of therapy. Viriom is also advancing long-acting formulations including once-weekly oral tablets and monthly injectable nanoformulations, with regulatory submissions under review in multiple countries including Thailand, China, Colombia, Indonesia, and South Africa.PR NewswireViriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected PatientsViriom Inc announced the initiation of a Phase 2a study evaluating the efficacy of its long-acting injectable nanoformulation of VM1500A (VM-1500A-LAI) in HIV-infected patients. Phase 1 trial data showed that the intramuscular injection maintained plasma drug concentrations above therapeutic thresholds for 4 to 8 weeks with no severe drug-related adverse events reported. The company is also exploring the formulation's potential for pre-exposure prophylaxis (PrEP), following the approval of its oral prodrug elsulfavirine (Elpida) in Russia.PR NewswireViriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate elsulfavirine as a treatment for COVID-19, enrolling approximately 240 patients in a randomized, open-label, multicenter trial at medical centers primarily across Russia and EAEU countries, beginning in May 2020. The study will assess two dosing regimens (5-day and 10-day) of elsulfavirine 1200mg loading dose followed by 200mg or 400mg daily in combination with azithromycin, with the primary objective measuring proportion of participants discharged by day 14. The company also indicated plans to investigate elsulfavirine in combination with favipiravir, manufactured by its affiliated ChemRar Group, for treating severe COVID-19 infection.PR NewswireViriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19; also working with global health authorities to determine the efficacy and safety of Elpida and its otherViriom Inc announced it is supporting the experimental use of its HIV medicine Elpida (elsulfavirine) and experimental flu drug candidates AV5080, AV5124, and AV5126 as potential COVID-19 treatments, having donated these medicines to Chinese and Russian governments in February 2020. The company is collaborating with the Chinese Center for Disease Control and Prevention, Russia's Ministry of Health, and select US and global health authorities to evaluate the antiviral activity of these drugs against COVID-19. Viriom is also working with industry partners including China Medical Systems Holdings, Insilico Medicines, and Molsoft, along with research institutions in China, Russia, and South Korea to advance this research.PR NewswireViriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral FormulationViriom Inc. has launched Segment I and II reproductive toxicity studies for its investigational HIV therapy, Elpida (elsulfavirine), in a once-weekly oral formulation. These preclinical studies are critical steps for the FDA drug approval process and are being executed by SRI International and Covance with support from the National Institute of Allergy and Infectious Diseases. The goal is to bring this long-acting formulation to the US market.PR NewswireViriom Wins Grant Award to Establish Affiliate in Mainland ChinaViriom Inc., a San Diego-based pharmaceutical company focused on HIV and infectious disease treatments, has won a grant award from the city of Shaoxing in Zhejiang province, China, to establish its affiliate in Mainland China. The company, which opened a Beijing representative office in 2017 and is also establishing an affiliate in Hong Kong, plans to partner with local pharmaceutical manufacturers and distributors as part of its five-year drug development strategy targeting markets in Greater China, Thailand, and Indonesia where over 5 million people live with HIV. The global HIV treatment and prophylaxis market in developing markets is estimated at $2.5 billion, projected to grow to $3.5 billion by 2025.PR NewswireViriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource ProgramViriom Inc., a clinical-stage antiviral company based in San Diego, has announced a collaboration with NIH/NIAID and Division of AIDS through the Long-Acting/Extended Release Antiviral Resource Program (LEAP) to advance its long-acting antiviral drug development. As part of the partnership, Viriom will work with the pharmacology core at the University of Liverpool to apply advanced quantitative pharmacology methods to analyze long-acting injection and once-weekly oral formulations of its investigational drug elsulfavirine (Elpida). The collaboration aims to accelerate the development and clinical testing of these formulations for treating and preventing HIV infection globally.